Author Archives: Kerri Fitzgerald

Safety and Efficacy of Belatacept as Immunotherapy in Kidney Transplant Recipients

Cyclosporine and tacrolimus, calcineurin inhibitors (CNIs), are commonly used as immunosuppressive therapy in patients who have undergone kidney transplantation. According to Josep M. Grinyó, MD, PhD, and colleagues in Buenos Aires, Argentina, those agents may be associated with patient comorbidity via nephrotoxicity and cardiovascular risk (hypertension, hypercholesterolemia, and diabetes mellitus), as well as transplant loss via chronic transplant injury. The ... Read More »

Tolvaptan Reduces Incidence of Kidney Pain in Patients with ADPKD

Patients with autosomal dominant polycystic kidney disease (ADPKD) often experience pain, a symptom reported early in the course of the disease. The pain associated with ADPKD can be severe and a challenge to manage as well as a complication that has an adverse effect on a patient’s quality of life. ADPKD-related acute pain may be caused by cyst hemorrhage, infection, ... Read More »

Risk Factors for Development of ESRD in Patients with IgA Nephrology

IgA nephropathy (IgAN) accounts for 45.36% of primary glomerular disease in China; it is also a leading cause of end-stage renal disease (ESRD). Approximately 30% of patients with IgAN progressed to ESRD within 10 to 20 years; however, in some patients, disease progression was more rapid, with ESRD occurring within 10 years. Previous studies found associations between various clinical and ... Read More »

Care Coordination Program Improved Outcomes and Reduced Costs

Orlando—Chronic kidney disease (CKD) exacts a burden on healthcare resources and is a serious public health concern. Beverly Everett, MD, and colleagues at Cigna Health and Life Insurance Company recently designed a study to assess the impact on outcomes of utilization of a pilot program designed to identify and engage CKD patients who are at risk for progression from CKD ... Read More »

Uncontrolled Gout among Patients with Chronic Kidney Disease

Orlando–Gout, caused by primarily by elevated serum uric acid in the blood, is the most common form of inflammatory arthritis. Recommendations in guidelines from the American College of Rheumatology call for lowering serum uric acid levels to <6 mg/dL for all patients with gout. Elevated serum uric acid is also associated with chronic kidney disease and results of previous studies ... Read More »

Dialysate Potassium Level and Adverse Events in Patients on Hemodialysis

In patients requiring hemodialysis, sudden death is a leading cause of death; 27% of all deaths in that patient population are attributable to arrhythmic mechanisms. In patients on maintenance hemodialysis three times a week, these events tend to cluster in the period just prior to the first dialysis session of the week when fluid overload and levels of various uremic ... Read More »

Specialized Disease Management Program Reduced Costs and Inpatient Admissions

Orlando—Optum’s Disease Management (DM) program utilizes communication via telephone and hard copy between renal specialty nurses and patients and healthcare providers to enhance patients’ knowledge of chronic kidney disease (CKD) and ways to maximize their healthcare. Employers purchase the DM program to enable patient-access. In 2016, a meta-analysis of the efficacy of DM programs focused on CKD demonstrated improved quality ... Read More »

Treating Children and Adolescents with ESRD: A Guide for Nephrologists

It is rare for children to be diagnosed with end-stage renal disease (ESRD); there are approximately 8500 children with ESRD in the United States, according to the most recent US Renal Data System report. Each year, approximately 1500 children in the United States develop ESRD; two-thirds of those patients initiate treatment with hemodialysis and one-third initiate treatment with peritoneal dialysis. ... Read More »

July/August 2017: Abstract Roundup

CHRONIC KIDNEY DISEASE Benefits of Phosphorus Binder Use among Non-Dialysis CKD Patients American Journal of Nephrology. 2017;45(5);431-441. It is unknown whether the benefits of phosphorus binders extend to patients with chronic kidney disease (CKD) but without end-stage renal disease. In a retrospective cohort study conducted by Simran Bhandari, MD, and colleagues, the researchers sought to evaluate phosphorus binder use and ... Read More »